List view / Grid view

Zelluna Immunotherapy

 

article

TCR therapy – an attractive alternative to CAR T

24 March 2020 | By

Chimeric antigen receptor (CAR) T-cell therapies have produced encouraging clinical outcomes, demonstrating their therapeutic potential in mitigating tumour development. However, another form of T-cell immunotherapy based on T-cell receptors (TCR) has also shown great potential in this field. Here, Nikki Withers speaks to Miguel Forte who elaborates on the process…